@article{3115964,
    title = "Amisulpride-induced hyperprolactinemia is reversible following
discontinuation",
    author = "Paparrigopoulos, Thomas and Liappas, John and Tzavellas, Elias and and Mourikis, Iraklis and Soldatos, Constantin",
    journal = "Progress in Neuro-Psychopharmacology and Biological Psychiatry",
    year = "2007",
    volume = "31",
    number = "1",
    pages = "92-96",
    publisher = "PERGAMON-ELSEVIER SCIENCE LTD",
    issn = "0278-5846",
    doi = "10.1016/j.pnpbp.2006.07.006",
    keywords = "amisulpride; antipsychotics; hyperprolactinaemia; prolactin",
    abstract = "Background: Although amisulpride is considered to be a prolactin-raising
atypical antipsychotic drug, a limited number of studies have documented
the extent of its prolactin-elevating properties. In the present study
the effect of amisulpride on plasma levels of prolactin and the
reversibility of this untoward side effect were investigated.
Methods: 17 patients with various diagnoses received amisulpride (50-800
mg/day) or a combination of amisulpride plus other medication as needed.
Plasma prolactin was determined 26.7 +/- 9.4 days (range: 13-50 days)
after initiation of treatment and in 3 cases after a much longer period,
and 14-51 days following its withdrawal.
Results: All patients on amisulpride had hyperprolactinemia, (mean +/-
S.D. prolactin levels: 62.5 +/- 33.0 ng/ml) with females exhibiting
considerably higher prolactin levels than males. Following amisulpride
discontinuation prolactin levels were significantly (p < 000) reduced
(mean S.D. prolactin levels: 12.3 +/- 6.7 ng/ml). No significant
correlation was detected between prolactin levels and either amisulpride
dosage or duration of administration.
Conclusion: Amisulpride has a pronounced prolactin-elevating effect
which appears to be independent of dosage and duration of
administration. Hyperprolactinemia rapidly reverses following
amisulpride discontinuation. (c) 2006 Elsevier Inc. All rights reserved."
}